The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

The Harvard Drug Group would like to inform you of a recall notice involving ChlorproMAZINE Hydrochloride Tablets, USP, 25 mg, 50 mg, 100 mg, and 200 mg.

This recall has been initiated by Zydus Pharmaceuticals (USA) Inc. due to an evaluation carried out for the drug product as per the FDA guidance on NDSRI (N-Nitroso Desmethyl Chlorpromazine) evaluation and it was identified that the batches were not meeting the FDA recommended limit. Consumption of the affected product may carry a potential risk of carcinogenicity.

We began shipping this product on June 24, 2024.

Product Name	Package Description	Brand Name	NDC	Lot Number	Expiration Date
ChlorproMAZINE HCl Tablets, USP, 25 mg	50 Unit Doses	Major®	0904-7130- 06	N01943	02/2026
	(10 x 5 blister packs)			N02025	02/2026
	100 Unit Doses	Major®	0904-7130- 61	N01954	11/2025
	(10 x 10 blister packs)			N02024	02/2026
ChlorproMAZINE HCl Tablets, USP, 50 mg	100 Unit Doses	Major®	0904-7131- 61	N02009	02/2026
	(10 x 10 blister packs)			N02026	02/2026
ChlorproMAZINE HCl Tablets, USP, 100 mg	100 Unit	Major®	0904-7132- 61	N01920	12/2025
	Doses			N02023	02/2026
	(10 x 10 blister packs)			N02202	06/2026
	100 Unit			N01928	09/2025
	Doses	Major®		N02008	03/2026

ChlorproMAZINE HCl Tablets, USP, 200 mg (10 x 10 blister packs) 0904-7133-61

N02071

02/2026